
Keely May McNamara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3344943/publications.pdf

Version: 2024-02-01



KEELY MAY MCNAMADA

#	Article	IF	CITATIONS
1	The role of mineralocorticoids and glucocorticoids under the impact of $11\hat{l}^2$ -hydroxysteroid dehydrogenase in human breast lesions. Medical Molecular Morphology, 2022, , .	1.0	Ο
2	The importance of mass spectrometry in unravelling steroid action in breast cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 57-62.	1.4	2
3	Progesteron receptor expression in insulin producing cells of neuroendocrine neoplasms. Journal of Steroid Biochemistry and Molecular Biology, 2020, 201, 105694.	2.5	3
4	Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells. Hormones and Cancer, 2020, 11, 87-96.	4.9	12
5	Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling. Breast Cancer Research and Treatment, 2020, 180, 97-110.	2.5	16
6	Abstract P3-02-10: The possible association among breast cancer, diabetes mellitus and GLP-1 receptor. , 2020, , .		0
7	Abstract P6-01-01: A study of clinical outcome and biomarker profiles of Japanese breast cancer patients according to mammographic density. , 2020, , .		0
8	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. IScience, 2019, 21, 341-358.	4.1	29
9	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. Endocrine Connections, 2019, 8, R10-R26.	1.9	33
10	The role of 17βHSDs in breast tissue and breast cancers. Molecular and Cellular Endocrinology, 2019, 489, 32-44.	3.2	5
11	Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2019, 173, 275-288.	2.5	27
12	S100P and Ezrin promote trans-endothelial migration of triple negative breast cancer cells. Cellular Oncology (Dordrecht), 2019, 42, 67-80.	4.4	33
13	The expression of sex steroid receptors and sex steroid–synthesizing/metabolizing enzymes in metastasized lymph nodes of prostate cancer. Human Pathology, 2019, 84, 124-132.	2.0	2
14	Progesterone arrested cell cycle progression through progesterone receptor isoform A in pancreatic neuroendocrine neoplasm. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 243-253.	2.5	4
15	Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients. Breast Cancer, 2018, 25, 489-496.	2.9	10
16	Improved detectability of sex steroids from frozen sections of breast cancer tissue using GC-triple quadrupole-MS. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 185-192.	2.5	14
17	In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics. British Journal of Cancer, 2018, 118, 1208-1216.	6.4	11
18	Possible roles for glucocorticoid signalling in breast cancer. Molecular and Cellular Endocrinology, 2018, 466, 38-50.	3.2	25

KEELY MAY MCNAMARA

#	Article	IF	CITATIONS
19	MCE – Special issue on updates on steroid signalling in breast cancer. Molecular and Cellular Endocrinology, 2018, 466, 1.	3.2	1
20	Randomized trial of aromatherapy versus conventional care for breast cancer patients during perioperative periods. Breast Cancer Research and Treatment, 2017, 162, 523-531.	2.5	23
21	Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors. Life Sciences, 2017, 190, 15-20.	4.3	13
22	Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma. Breast Cancer Research and Treatment, 2017, 166, 709-723.	2.5	13
23	The presence and impact of estrogen metabolism on the biology of triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 161, 213-227.	2.5	18
24	The use of chemosensitizers to enhance the response to conventional therapy in triple-negative breast cancer patients. Breast Cancer Management, 2017, 6, 127-131.	0.2	11
25	Virilism and Ectopic Expression of HSD17B5 in Mature Cystic Teratoma. Tohoku Journal of Experimental Medicine, 2017, 241, 125-129.	1.2	1
26	Serotonin receptor 4 (5-hydroxytryptamine receptor Type 4) regulates expression of estrogen receptor beta and cell migration in hormone-naive prostate cancer. Indian Journal of Pathology and Microbiology, 2017, 60, 33-37.	0.2	4
27	Androgen and breast cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 249-256.	2.3	15
28	In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocrine-Related Cancer, 2016, 23, R323-R335.	3.1	24
29	Reply to comments to "Letter to the Editor: comment on Azmahani et al. steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions― Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 178-180.	2.5	1
30	Estrogen receptor β in Merkel cell carcinoma: its possible roles in pathogenesis. Human Pathology, 2016, 56, 128-133.	2.0	5
31	How far have we come in terms of estrogens in breast cancer? [Review]. Endocrine Journal, 2016, 63, 413-424.	1.6	8
32	Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification. Expert Opinion on Therapeutic Targets, 2016, 20, 705-720.	3.4	49
33	The Role of Androgen Under Normal and Pathological Conditions in Sebaceous Glands: The Possibility of Target Therapy. Current Molecular Pharmacology, 2016, 9, 311-319.	1.5	5
34	Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. BMC Cancer, 2015, 15, 699.	2.6	16
35	Androgen Receptor and Enzymes in Lymph Node Metastasis and Cancer Reoccurrence in Triple-Negative Breast Cancer. International Journal of Biological Markers, 2015, 30, 184-189.	1.8	17
36	Hypoelectrolytic isoosmotic solution for infusion prevents saline-induced ultrastuructural artifacts of renal biopsy specimens. Pathology International, 2015, 65, 374-378.	1.3	0

#	Article	IF	CITATIONS
37	Clinical Significance of Subtype Classification in Metastatic Lymph Nodes of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. International Journal of Biological Markers, 2015, 30, 174-183.	1.8	2
38	Beyond the C18 frontier: Androgen and glucocorticoid metabolism in breast cancer tissues. Steroids, 2015, 103, 115-122.	1.8	6
39	11β-Prostaglandin F2α, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. Molecular and Cellular Endocrinology, 2015, 413, 236-247.	3.2	20
40	KLF15 in breast cancer: a novel tumor suppressor?. Cellular Oncology (Dordrecht), 2015, 38, 227-235.	4.4	61
41	Is there a role for segmental adrenal venous sampling and adrenal sparing surgery in patients with primary aldosteronism?. European Journal of Endocrinology, 2015, 173, 465-477.	3.7	62
42	Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary Paget disease. Human Pathology, 2015, 46, 1662-1669.	2.0	18
43	3βHSD and CYB5A double positive adrenocortical cells during adrenal development/aging. Endocrine Research, 2015, 40, 8-13.	1.2	20
44	The intracrinology of breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2015, 145, 172-178.	2.5	61
45	Renal epithelioid angiomyolipoma with malignant features: Histological evaluation and novel immunohistochemical findings. Pathology International, 2014, 64, 133-141.	1.3	21
46	Complexities of androgen receptor signalling in breast cancer. Endocrine-Related Cancer, 2014, 21, T161-T181.	3.1	113
47	Analysis of clinically relevant values of Ki-67 labeling index in Japanese breast cancer patients. Breast Cancer, 2014, 21, 325-333.	2.9	11
48	Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Research and Treatment, 2014, 145, 281-293.	2.5	34
49	Glutamate receptors and the regulation of steroidogenesis in the human adrenal gland: The metabotropic pathway. Molecular and Cellular Endocrinology, 2014, 382, 170-177.	3.2	23
50	Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 268-279.	2.5	20
51	The Correlation between Body Mass Index and Breast Cancer Risk or Estrogen Receptor Status in Okinawan Women. Tohoku Journal of Experimental Medicine, 2014, 234, 169-174.	1.2	16
52	GATA6, SF1, NGFIB and DAX1 in the remodeled subcapsular zones in primary aldosteronism. Endocrine Journal, 2014, 61, 393-401.	1.6	5
53	Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Science, 2014, 105, 1503-1509.	3.9	9
54	Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology, 2013, 44, 2338-2345.	2.0	12

KEELY MAY MCNAMARA

#	Article	IF	CITATIONS
55	Androgen receptor in triple negative breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 2013, 133, 66-76.	2.5	107
56	Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer. Prostate, 2013, 73, 590-595.	2.3	42
57	HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research, 2013, 15, R30.	5.0	44
58	Androgenic pathway in triple negative invasive ductal tumors: Its correlation with tumor cell proliferation. Cancer Science, 2013, 104, 639-646.	3.9	71
59	Estrogen-related receptor \hat{I}_{\pm} in normal adrenal cortex and adrenocortical tumors: Involvement in development and oncogenesis. Molecular and Cellular Endocrinology, 2013, 365, 207-211.	3.2	16
60	Prostate epithelial AR inactivation leads to increased intraprostatic androgen synthesis. Prostate, 2013, 73, 316-327.	2.3	7
61	Phase Two Steroid Metabolism and Its Roles in Breast and Prostate Cancer Patients. Frontiers in Endocrinology, 2013, 4, 116.	3.5	14
62	Ask the Experts: Role(s) of androgens in breast cancer biology and treatment. Breast Cancer Management, 2013, 2, 101-104.	0.2	0
63	A Patient with POEMS Syndrome: The Pathology of Glomerular Microangiopathy. Tohoku Journal of Experimental Medicine, 2013, 231, 229-234.	1.2	8
64	Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy. Current Molecular Pharmacology, 2013, 5, 392-400.	1.5	2
65	The mouse as a model to investigate sex steroid metabolism in the normal and pathological prostate. Journal of Steroid Biochemistry and Molecular Biology, 2012, 131, 107-121.	2.5	6
66	Longâ€Term corticosterone treatment induced lobeâ€specific pathology in mouse prostate. Prostate, 2011, 71, 289-297.	2.3	12
67	Anterior prostate epithelial AR inactivation modifies estrogen receptor expression and increases estrogen sensitivity. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E727-E735.	3.5	8
68	Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography–tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 611-618.	2.5	102
69	Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E1335-E1343.	3.5	29
70	Severe Subfertility in Mice with Androgen Receptor Inactivation in Sex Accessory Organs But Not in Testis. Endocrinology, 2008, 149, 3330-3338.	2.8	39
71	Dynorphin Knockout Reduces Fat Mass and Increases Weight Loss during Fasting in Mice. Molecular Endocrinology, 2007, 21, 1722-1735.	3.7	29